VANCOUVER, British Columbia--(BUSINESS WIRE)--Nov. 23, 2005--Inflazyme Pharmaceuticals Ltd. (TSX:IZP) today announced preliminary results of the oral, multiple dose Phase I study conducted in healthy volunteers by their partner Helicon Therapeutics, Inc. of New York.
